Após nove meses de investigação, a Agência Europeia de Medicamentos concluiu que a semaglutida — princípio ativo do Ozempic e do Wegovy — não apresenta evidências de associação com pensamentos suicidas. A conclusão, alinhada à dos reguladores americanos, encerra uma fase de incerteza iniciada quando a Islândia sinalizou três casos suspeitos. O episódio lembra que, à medida que milhões adotam novas terapias, a vigilância regulatória não é burocracia, mas uma forma de cuidado coletivo — especialmente quando a história já registrou retiradas dolorosas, como a do Acomplia em 2008.
Folha de S.Paulo
· Apr 12, 2024
· health
· 3 min de lectura
High
Verificación: Verificado
EU regulator finds no link between Ozempic and suicidal thoughts after 9-month review
◉
Health & Medicine
2746 artículos relacionados
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% coincidencia
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% coincidencia
Brazil Gets New Blood Test for Early Alzheimer's Detection
Olhar Digital · 90% coincidencia
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% coincidencia
Medical Expert Warns of Tirzepatide Risks, Emphasizes Need for Profess…
UNIPAR · 90% coincidencia
Cobertura Relacionada
G1 · Aug 20
Pai agradece médicos após morte de gêmeas unidas pela cabeça: 'mais vitórias que derrotas'
Pai das gêmeas unidas pela cabeça que morreram em cirurgia de separação agradece empenho de mais de 50 profissionais do …
Folha de S.Paulo · Aug 20 Selton Mello se emociona ao receber Kikito de Cristal em GramadoSelton Mello recebeu o Kikito de Cristal no Festival de Gramado e se emocionou ao lembrar que era a primeira vez receben…
G1 · Aug 20 CEMEI Amiguinhos da Vila inaugura prédio moderno com capacidade para 320 alunosInaugurado novo prédio do CEMEI Amiguinhos da Vila em Montes Claros, com capacidade para 320 alunos, oito salas de aula,…
Folha de S.Paulo · Aug 20 Hepatites D e E circulam no Brasil e preocupam especialistasRevisão de 200 estudos com dados de 14,5 milhões de pessoas revela que hepatites D e E circulam no Brasil com prevalênci…
Sesgo y Encuadre
⚖
Article presents EU regulator's reassuring conclusion on Ozempic safety with minimal critical context, favoring pharmaceutical industry narrative.
Bias Direction
center-right
Confidence
MED
Reassurance framing emphasizing regulatory clearance and stock market gains, with limited exploration of initial safety concerns or ongoing monitoring limitations.
descartada (dismissed/ruled out) - suggests concerns were unfounded rather than investigated
não encontrou evidências (found no evidence) - definitive language despite ongoing monitoring
as ações da Novo Nordisk aumentaram quase 2% (stock increased) - implies market validation of safety
Patient testimonies or advocacy groups who reported adverse effects
Independent medical researchers or skeptical experts questioning the review methodology
Details on the three Icelandic cases that triggered the investigation
Limitations of the 9-month review period or data gaps acknowledged by regulators
Comparative analysis with other GLP-1 drugs and their safety profiles
Long-term monitoring plans or post-market surveillance details
Impacto Geopolítico
🌎
EU regulator clears semaglutida (Ozempic/Wegovy) of suicide risk after 9-month review, aligning with US findings and boosting Novo Nordisk's market position across transatlantic markets.
Escalation Risk
low
Confidence
HIGH
European Union
United States
Iceland
Denmark
Novo Nordisk strengthens its regulatory standing and market dominance in the lucrative GLP-1 agonist sector across EU and US markets. EU-US regulatory alignment enhances pharmaceutical industry confidence and reduces fragmentation risks. Iceland's initial safety concerns were overridden by larger regulatory bodies, reflecting power concentration in major regulatory agencies.
Similar to the 2010s statin controversy where initial safety concerns were systematically investigated and largely dismissed by major regulators, reinforcing trust in pharmaceutical oversight mechanisms while occasionally frustrating patient advocacy groups.
Lente Económico
📈
EU regulator clears semaglutida (Ozempic/Wegovy) of suicide risk after 9-month review, boosting Novo Nordisk stock ~2% and reducing regulatory uncertainty for GLP-1 drug class.
Market Signal
bullish
Confidence
HIGH
Pharmaceuticals & Biotechnology
Healthcare & Medical Devices
Insurance (Health)
Wellness & Weight Management
Consumers gain confidence in GLP-1 medications for diabetes and weight loss without psychiatric safety concerns. Reduced hesitation for prescription adoption and continued off-label use. Lower insurance claim denials related to psychiatric adverse events.
Regulatory clearance reduces likelihood of label warnings or market restrictions in EU. May accelerate approval timelines for competing GLP-1 drugs. Establishes precedent for pharmacovigilance standards on psychiatric safety in metabolic drugs. Potential for harmonized international safety guidance.